Similarities and Differences in the Expression of Drug-Metabolizing Enzymes between Human Hepatic Cell Lines and Primary Human Hepatocytes

In addition to primary human hepatocytes, hepatoma cell lines, and transfected nonhepatoma, hepatic cell lines have been used for pharmacological and toxicological studies. However, a systematic evaluation and a general report of the gene expression spectra of drug-metabolizing enzymes and transport...

Full description

Saved in:
Bibliographic Details
Published inDrug metabolism and disposition Vol. 39; no. 3; pp. 528 - 538
Main Authors Guo, Lei, Dial, Stacey, Shi, Leming, Branham, William, Liu, Jie, Fang, Jia-Long, Green, Bridgett, Deng, Helen, Kaput, Jim, Ning, Baitang
Format Journal Article
LanguageEnglish
Published Bethesda, MD Elsevier Inc 01.03.2011
American Society for Pharmacology and Experimental Therapeutics
The American Society for Pharmacology and Experimental Therapeutics
Subjects
Online AccessGet full text
ISSN0090-9556
1521-009X
1521-009X
DOI10.1124/dmd.110.035873

Cover

Abstract In addition to primary human hepatocytes, hepatoma cell lines, and transfected nonhepatoma, hepatic cell lines have been used for pharmacological and toxicological studies. However, a systematic evaluation and a general report of the gene expression spectra of drug-metabolizing enzymes and transporters (DMETs) in these in vitro systems are not currently available. To fill this information gap and to provide references for future studies, we systematically characterized the basal gene expression profiles of 251 drug-metabolizing enzymes in untreated primary human hepatocytes from six donors, four commonly used hepatoma cell lines (HepG2, Huh7, SK-Hep-1, and Hep3B), and one transfected human liver epithelial cell line. A large variation in DMET expression spectra was observed between hepatic cell lines and primary hepatocytes, with the complete absence or much lower abundance of certain DMETs in hepatic cell lines. Furthermore, the basal DMET expression spectra of five hepatic cell lines are summarized, providing references for researchers to choose carefully appropriate in vitro models for their studies of drug metabolism and toxicity, especially for studies with drugs in which toxicities are mediated through the formation of reactive metabolites.
AbstractList In addition to primary human hepatocytes, hepatoma cell lines, and transfected nonhepatoma, hepatic cell lines have been used for pharmacological and toxicological studies. However, a systematic evaluation and a general report of the gene expression spectra of drug-metabolizing enzymes and transporters (DMETs) in these in vitro systems are not currently available. To fill this information gap and to provide references for future studies, we systematically characterized the basal gene expression profiles of 251 drug-metabolizing enzymes in untreated primary human hepatocytes from six donors, four commonly used hepatoma cell lines (HepG2, Huh7, SK-Hep-1, and Hep3B), and one transfected human liver epithelial cell line. A large variation in DMET expression spectra was observed between hepatic cell lines and primary hepatocytes, with the complete absence or much lower abundance of certain DMETs in hepatic cell lines. Furthermore, the basal DMET expression spectra of five hepatic cell lines are summarized, providing references for researchers to choose carefully appropriate in vitro models for their studies of drug metabolism and toxicity, especially for studies with drugs in which toxicities are mediated through the formation of reactive metabolites.
In addition to primary human hepatocytes, hepatoma cell lines, and transfected nonhepatoma, hepatic cell lines have been used for pharmacological and toxicological studies. However, a systematic evaluation and a general report of the gene expression spectra of drug-metabolizing enzymes and transporters (DMETs) in these in vitro systems are not currently available. To fill this information gap and to provide references for future studies, we systematically characterized the basal gene expression profiles of 251 drug-metabolizing enzymes in untreated primary human hepatocytes from six donors, four commonly used hepatoma cell lines (HepG2, Huh7, SK-Hep-1, and Hep3B), and one transfected human liver epithelial cell line. A large variation in DMET expression spectra was observed between hepatic cell lines and primary hepatocytes, with the complete absence or much lower abundance of certain DMETs in hepatic cell lines. Furthermore, the basal DMET expression spectra of five hepatic cell lines are summarized, providing references for researchers to choose carefully appropriate in vitro models for their studies of drug metabolism and toxicity, especially for studies with drugs in which toxicities are mediated through the formation of reactive metabolites.In addition to primary human hepatocytes, hepatoma cell lines, and transfected nonhepatoma, hepatic cell lines have been used for pharmacological and toxicological studies. However, a systematic evaluation and a general report of the gene expression spectra of drug-metabolizing enzymes and transporters (DMETs) in these in vitro systems are not currently available. To fill this information gap and to provide references for future studies, we systematically characterized the basal gene expression profiles of 251 drug-metabolizing enzymes in untreated primary human hepatocytes from six donors, four commonly used hepatoma cell lines (HepG2, Huh7, SK-Hep-1, and Hep3B), and one transfected human liver epithelial cell line. A large variation in DMET expression spectra was observed between hepatic cell lines and primary hepatocytes, with the complete absence or much lower abundance of certain DMETs in hepatic cell lines. Furthermore, the basal DMET expression spectra of five hepatic cell lines are summarized, providing references for researchers to choose carefully appropriate in vitro models for their studies of drug metabolism and toxicity, especially for studies with drugs in which toxicities are mediated through the formation of reactive metabolites.
Author Liu, Jie
Fang, Jia-Long
Dial, Stacey
Deng, Helen
Guo, Lei
Green, Bridgett
Ning, Baitang
Shi, Leming
Kaput, Jim
Branham, William
Author_xml – sequence: 1
  givenname: Lei
  surname: Guo
  fullname: Guo, Lei
– sequence: 2
  givenname: Stacey
  surname: Dial
  fullname: Dial, Stacey
– sequence: 3
  givenname: Leming
  surname: Shi
  fullname: Shi, Leming
– sequence: 4
  givenname: William
  surname: Branham
  fullname: Branham, William
– sequence: 5
  givenname: Jie
  surname: Liu
  fullname: Liu, Jie
– sequence: 6
  givenname: Jia-Long
  surname: Fang
  fullname: Fang, Jia-Long
– sequence: 7
  givenname: Bridgett
  surname: Green
  fullname: Green, Bridgett
– sequence: 8
  givenname: Helen
  surname: Deng
  fullname: Deng, Helen
– sequence: 9
  givenname: Jim
  surname: Kaput
  fullname: Kaput, Jim
– sequence: 10
  givenname: Baitang
  surname: Ning
  fullname: Ning, Baitang
  email: baitang.ning@fda.hhs.gov
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23928834$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/21149542$$D View this record in MEDLINE/PubMed
BookMark eNp1UsFuEzEQXaEimhauHNFeEKcN9tre2BcklAaKFAQSIHGzHO84HbRrB9sppJ_AV-MoKRSkXjxj-b0388ZzVp344KGqnlIypbTlL_uxLwmZEibkjD2oJlS0tCFEfT2pJiWQRgnRnVZnKX0jhHLO1KPqtKWUK8HbSfXrE444mIgZIdXG9_UFOgcRvC139HW-gnrxcxMhJQy-Dq6-iNt18x6yWYUBb9Cv64W_2Y0FvoL8A8DXl9vRlBM2JqOt5zAM9RL9Uf9jxNHE3V1QsLsM6XH10JkhwZNjPK--vFl8nl82yw9v381fLxsrGM-NcIIVkzOrTEs4dZR1q44QyfpezZxVshiTYsZm0hT7rVs56iTtFLTWcUUMO69eHXQ329UIvQWfoxn05tCXDgb1vy8er_Q6XGtGOiqELAIvjgIxfN9CynrEZItL4yFsk5aiVZTwThTks7ul_tS4nX8BPD8CTLJmcNF4i-kvjqlWSsYLjh9wNoaUIjhtMZfphn2HOGhK9H4ddFmHkhB9WIdCm_5Hu1W-lyAPBCgfcI0QdbK434UeI9is-4D3UX8DFBzLbw
CODEN DMDSAI
CitedBy_id crossref_primary_10_1155_2015_821761
crossref_primary_10_1517_17425255_2012_685159
crossref_primary_10_1016_j_phrs_2019_04_016
crossref_primary_10_1016_j_tiv_2021_105156
crossref_primary_10_1016_j_tim_2020_06_005
crossref_primary_10_1080_17460441_2017_1271784
crossref_primary_10_3389_fphar_2022_826395
crossref_primary_10_3390_ijms25063265
crossref_primary_10_1016_j_jhep_2015_11_013
crossref_primary_10_1111_liv_14942
crossref_primary_10_1016_j_antiviral_2023_105756
crossref_primary_10_1016_j_ijpharm_2019_118693
crossref_primary_10_1186_s13287_025_04139_2
crossref_primary_10_1038_s41598_019_47114_7
crossref_primary_10_2174_1871530319666191129120253
crossref_primary_10_1016_j_bbalip_2015_10_008
crossref_primary_10_1080_01480545_2016_1255953
crossref_primary_10_1016_S1875_5364_18_30124_9
crossref_primary_10_1007_s00204_018_2196_x
crossref_primary_10_1007_s00204_020_02706_5
crossref_primary_10_1016_j_tox_2016_09_012
crossref_primary_10_1124_dmd_114_062836
crossref_primary_10_1002_cptx_66
crossref_primary_10_1089_aivt_2017_0022
crossref_primary_10_3390_ijms25073610
crossref_primary_10_1016_j_apmt_2024_102374
crossref_primary_10_1038_s41598_020_62286_3
crossref_primary_10_1002_jcp_24148
crossref_primary_10_1007_s00204_014_1265_z
crossref_primary_10_1038_ncomms4739
crossref_primary_10_1038_s41598_022_18174_z
crossref_primary_10_1080_26896583_2022_2044242
crossref_primary_10_1016_j_fct_2021_112355
crossref_primary_10_1093_toxsci_kfu238
crossref_primary_10_3390_cancers11121873
crossref_primary_10_1016_j_bioorg_2023_106801
crossref_primary_10_1093_toxsci_kft254
crossref_primary_10_1007_s13577_017_0175_9
crossref_primary_10_1124_dmd_117_078238
crossref_primary_10_1038_s41598_024_73827_5
crossref_primary_10_1016_j_rvsc_2017_08_006
crossref_primary_10_1177_2211068214566939
crossref_primary_10_1186_1755_8794_8_S2_S5
crossref_primary_10_1016_j_mrgentox_2017_12_005
crossref_primary_10_3390_mi12040418
crossref_primary_10_1080_26896583_2021_1880242
crossref_primary_10_1007_s00204_014_1215_9
crossref_primary_10_1016_j_biomaterials_2013_02_070
crossref_primary_10_1016_j_talanta_2022_123262
crossref_primary_10_2174_1389201021666200422090952
crossref_primary_10_3390_ijms222313135
crossref_primary_10_1155_2023_4399998
crossref_primary_10_1002_bit_28456
crossref_primary_10_1248_bpb_b17_00913
crossref_primary_10_30895_2312_7821_2023_379
crossref_primary_10_1016_j_apsb_2021_11_013
crossref_primary_10_1016_j_mrgentox_2018_06_020
crossref_primary_10_1038_s12276_022_00921_x
crossref_primary_10_1021_acs_est_0c03476
crossref_primary_10_1002_em_21817
crossref_primary_10_3390_ijms23179986
crossref_primary_10_1089_aivt_2015_0024
crossref_primary_10_1186_s40580_020_00228_5
crossref_primary_10_1016_j_tox_2024_153829
crossref_primary_10_1016_j_yexcr_2017_12_023
crossref_primary_10_1039_C5OB00427F
crossref_primary_10_1039_C6TX00101G
crossref_primary_10_1093_toxres_tfac017
crossref_primary_10_3389_fbioe_2018_00120
crossref_primary_10_1016_j_tiv_2013_07_010
crossref_primary_10_1016_j_taap_2014_07_007
crossref_primary_10_1007_s10616_020_00398_4
crossref_primary_10_1016_j_ejphar_2011_05_084
crossref_primary_10_1016_j_scitotenv_2021_151192
crossref_primary_10_1016_j_taap_2019_114790
crossref_primary_10_1093_mutage_gev058
crossref_primary_10_1016_j_etap_2018_06_010
crossref_primary_10_3390_v13010097
crossref_primary_10_1007_s00204_011_0733_y
crossref_primary_10_1007_s13346_022_01170_1
crossref_primary_10_1016_j_biochi_2015_07_003
crossref_primary_10_3390_pharmaceutics15041300
crossref_primary_10_51335_organoid_2022_2_e6
crossref_primary_10_1038_s41598_020_77106_x
crossref_primary_10_1093_toxsci_kfw173
crossref_primary_10_3389_fmed_2019_00265
crossref_primary_10_1016_j_fct_2015_08_030
crossref_primary_10_1016_j_jep_2014_06_038
crossref_primary_10_1016_j_ijbiomac_2021_06_174
crossref_primary_10_1016_j_tox_2024_153884
crossref_primary_10_1248_bpbreports_3_1_7
crossref_primary_10_1016_j_abb_2023_109536
crossref_primary_10_1016_j_tox_2016_11_014
crossref_primary_10_1016_j_bcp_2015_03_015
crossref_primary_10_1093_carcin_bgs182
crossref_primary_10_1016_j_dmpk_2018_03_003
crossref_primary_10_1111_1541_4337_12280
crossref_primary_10_1016_j_pt_2022_05_014
crossref_primary_10_1016_j_jinorgbio_2023_112252
crossref_primary_10_1007_s11419_020_00562_7
crossref_primary_10_1016_j_tox_2014_05_007
crossref_primary_10_1016_j_stemcr_2020_04_010
crossref_primary_10_1007_s10565_015_9301_1
crossref_primary_10_1124_dmd_123_001396
crossref_primary_10_1016_j_tiv_2015_04_001
crossref_primary_10_1016_j_fct_2014_06_013
crossref_primary_10_1021_tx400317p
crossref_primary_10_1021_acsami_1c14401
crossref_primary_10_3892_mmr_2016_4845
crossref_primary_10_1016_j_biomaterials_2012_03_034
crossref_primary_10_1016_j_yexcr_2015_07_004
crossref_primary_10_1007_s00204_016_1893_6
crossref_primary_10_1016_j_actbio_2016_04_042
crossref_primary_10_1016_j_jep_2013_10_021
crossref_primary_10_1021_acs_jmedchem_4c01341
crossref_primary_10_1038_s41536_022_00252_5
crossref_primary_10_1016_j_biomaterials_2012_08_065
crossref_primary_10_3390_bios12030160
crossref_primary_10_1016_S0022_3549_15_00190_2
crossref_primary_10_1242_bio_042192
crossref_primary_10_1038_s41598_017_09321_y
crossref_primary_10_1002_dta_3184
crossref_primary_10_1038_s41467_020_15058_6
crossref_primary_10_1093_toxsci_kfx122
crossref_primary_10_1186_s13568_020_01064_w
crossref_primary_10_1021_jacs_3c05704
crossref_primary_10_1038_s41746_024_01024_9
crossref_primary_10_1016_j_tiv_2023_105689
crossref_primary_10_1080_14756366_2021_1886093
crossref_primary_10_1128_AAC_01460_21
crossref_primary_10_1016_j_cbi_2021_109531
crossref_primary_10_3389_fgene_2021_767621
crossref_primary_10_1038_srep41238
crossref_primary_10_1021_acs_jmedchem_6b00382
crossref_primary_10_3389_fbioe_2022_845360
crossref_primary_10_1093_toxsci_kfs100
crossref_primary_10_1002_em_22157
crossref_primary_10_1016_j_isci_2023_106395
crossref_primary_10_1063_5_0206271
crossref_primary_10_1134_S1070363224060136
crossref_primary_10_1002_adma_202307673
crossref_primary_10_1097_MOG_0000000000000726
crossref_primary_10_1016_j_tox_2017_10_002
crossref_primary_10_1016_j_toxlet_2024_10_004
crossref_primary_10_1038_srep08534
crossref_primary_10_1016_j_celrep_2016_12_070
crossref_primary_10_1016_j_toxlet_2017_06_005
crossref_primary_10_1080_10408444_2020_1756219
crossref_primary_10_1016_j_biopha_2016_08_009
crossref_primary_10_1089_ten_teb_2016_0031
crossref_primary_10_1007_s00204_016_1694_y
crossref_primary_10_1016_j_yexcr_2017_10_017
crossref_primary_10_3389_fbioe_2023_1189726
crossref_primary_10_1124_dmd_122_000906
crossref_primary_10_1016_j_scr_2020_101732
crossref_primary_10_1016_j_etap_2015_10_010
crossref_primary_10_1371_journal_pone_0173825
crossref_primary_10_1002_em_22173
crossref_primary_10_18632_oncotarget_21821
crossref_primary_10_1021_mp500063y
crossref_primary_10_3390_mi8010027
crossref_primary_10_1515_hmbci_2023_0012
crossref_primary_10_1089_ars_2017_7086
crossref_primary_10_1002_btpr_2627
crossref_primary_10_4062_biomolther_2016_153
crossref_primary_10_1039_D5TB00074B
crossref_primary_10_1371_journal_pone_0060368
crossref_primary_10_3390_ma14216480
crossref_primary_10_1007_s00204_019_02576_6
crossref_primary_10_1016_j_bej_2022_108757
crossref_primary_10_3390_biomedicines11113059
crossref_primary_10_1093_mutage_ger021
crossref_primary_10_1089_aivt_2018_0020
crossref_primary_10_1016_j_tiv_2018_02_014
crossref_primary_10_1016_j_tiv_2018_02_013
crossref_primary_10_1128_AAC_00932_21
crossref_primary_10_1002_em_22197
crossref_primary_10_1016_j_fct_2017_09_042
crossref_primary_10_4162_nrp_2017_11_2_97
crossref_primary_10_1007_s00204_022_03329_8
crossref_primary_10_1302_2046_3758_103_BJR_2020_0412
crossref_primary_10_1016_j_toxlet_2013_05_641
crossref_primary_10_1016_j_cbi_2015_10_009
crossref_primary_10_1128_AAC_00530_12
crossref_primary_10_1186_s13007_019_0487_8
crossref_primary_10_1038_s41598_022_25777_z
crossref_primary_10_1016_j_jhazmat_2024_134589
crossref_primary_10_2147_IJN_S478574
crossref_primary_10_3390_toxins11070377
crossref_primary_10_1124_dmd_111_042465
crossref_primary_10_1080_03602532_2022_2064487
crossref_primary_10_1007_s00204_016_1775_y
crossref_primary_10_3390_ijms24098121
crossref_primary_10_3390_nu12051440
crossref_primary_10_1016_j_fct_2018_02_036
crossref_primary_10_1016_j_watres_2024_121562
crossref_primary_10_2133_dmpk_DMPK_12_RG_016
crossref_primary_10_1093_toxsci_kfu154
crossref_primary_10_1016_j_neuro_2015_10_014
crossref_primary_10_1016_j_actbio_2020_08_041
crossref_primary_10_3390_biomedicines12061200
crossref_primary_10_3390_cells11020305
crossref_primary_10_2174_0115701638278844231214115102
crossref_primary_10_1007_s00204_022_03381_4
crossref_primary_10_1080_00498254_2019_1683258
crossref_primary_10_3390_plants11212862
crossref_primary_10_1124_jpet_116_235044
crossref_primary_10_3390_ijms22031217
crossref_primary_10_1007_s11626_020_00451_8
crossref_primary_10_1016_j_biomaterials_2012_04_014
crossref_primary_10_1016_j_biomaterials_2020_120611
crossref_primary_10_1055_a_1934_5404
crossref_primary_10_1194_jlr_D120000726
crossref_primary_10_1517_17425255_2014_967680
crossref_primary_10_3390_nu14132768
crossref_primary_10_1371_journal_pone_0160285
crossref_primary_10_1016_j_bbadis_2018_08_038
crossref_primary_10_3233_JCB_189013
crossref_primary_10_1016_j_bcp_2018_06_026
crossref_primary_10_1016_j_jsps_2021_03_002
crossref_primary_10_1089_jmf_2019_0032
crossref_primary_10_2217_bmm_13_154
crossref_primary_10_1016_j_fct_2025_115382
crossref_primary_10_1016_j_bcp_2020_114173
crossref_primary_10_1007_s11356_018_2046_7
crossref_primary_10_3923_ijp_2019_229_237
crossref_primary_10_1124_dmd_115_067348
crossref_primary_10_1182_blood_2016_10_740241
crossref_primary_10_3390_bioengineering10020270
crossref_primary_10_1124_dmd_119_087676
crossref_primary_10_1093_toxsci_kfv117
crossref_primary_10_2174_1871530323666230411100121
crossref_primary_10_1016_j_tiv_2016_04_016
crossref_primary_10_1134_S1607672919060048
crossref_primary_10_1007_s11626_022_00711_9
crossref_primary_10_3390_ijerph110201855
crossref_primary_10_3389_fmedt_2020_611913
crossref_primary_10_1021_ic5028948
crossref_primary_10_1038_srep35633
crossref_primary_10_1002_2211_5463_12948
crossref_primary_10_1007_s10565_017_9392_y
crossref_primary_10_3892_etm_2017_4240
crossref_primary_10_1177_02611929221091269
crossref_primary_10_1016_j_aca_2019_04_013
crossref_primary_10_1186_s40779_022_00409_9
crossref_primary_10_1007_s00204_015_1599_1
crossref_primary_10_1093_mutage_ges030
crossref_primary_10_3390_molecules28073021
crossref_primary_10_1089_ten_tea_2023_0212
crossref_primary_10_1002_smll_202006055
Cites_doi 10.1016/j.hep.2003.09.034
10.1016/j.tig.2008.06.001
10.1016/S0928-0987(01)00135-X
10.1177/0091270007312153
10.1016/j.taap.2007.03.032
10.2174/138920008783331086
10.1016/S0014-5793(98)00746-7
10.1016/j.toxlet.2005.06.003
10.1016/j.bmc.2009.09.008
10.1124/dmd.31.8.1035
10.1093/toxsci/kfq026
10.1093/ajhp/59.21.2061
10.1016/j.taap.2010.01.012
10.1073/pnas.90.11.5123
10.1254/jphs.08122FP
10.1124/dmd.109.031831
10.2174/138920008786485128
10.1006/abbi.2001.2499
10.1016/j.tiv.2007.05.014
10.1124/dmd.105.006759
10.1016/S0076-6879(96)72044-X
10.1289/ehp.97105s4829
10.1080/03602530601093489
10.1016/0014-5793(88)81021-4
10.1159/000047798
10.1016/S0041-008X(03)00128-5
10.1371/journal.pbio.0060107
10.1101/gr.103341.109
10.1096/fasebj.10.2.8641560
10.1093/toxsci/kfn056
10.1080/03602530902843483
10.1016/j.cbi.2006.11.002
10.2174/138920008786049302
10.1080/00498250701534893
10.1016/j.jhazmat.2009.04.090
10.1016/j.tox.2004.02.008
10.2174/1389200033489424
10.1016/j.bbamcr.2003.10.017
ContentType Journal Article
Copyright 2011 American Society for Pharmacology and Experimental Therapeutics
2015 INIST-CNRS
U.S. Government work not protected by U.S. copyright
Copyright_xml – notice: 2011 American Society for Pharmacology and Experimental Therapeutics
– notice: 2015 INIST-CNRS
– notice: U.S. Government work not protected by U.S. copyright
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1124/dmd.110.035873
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1521-009X
EndPage 538
ExternalDocumentID PMC3061558
21149542
23928834
10_1124_dmd_110_035873
S0090955624057210
Genre Research Support, U.S. Gov't, P.H.S
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIDDK NIH HHS
  grantid: N01-DK-7-0004
– fundername: NLM NIH HHS
  grantid: HHSN267200700004G
– fundername: NLM NIH HHS
  grantid: HHSN267200700004C
– fundername: National Institutes of Health
  grantid: N01-DK-7-0004/HHSN267200700004C
GroupedDBID ---
.GJ
0R~
18M
2WC
4.4
53G
5GY
5RE
5VS
AAXUO
ABJNI
ABSQV
ACGFO
ACGFS
ACIWK
ACPRK
ADBBV
AENEX
AERNN
AFFNX
AFOSN
AFRAH
AI.
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
F9R
FDB
GX1
H13
HZ~
IH2
INIJC
KQ8
LSO
M41
O9-
OK1
P2P
R0Z
RHI
ROL
RPT
SJN
TR2
VH1
W8F
WH7
WOQ
YCJ
YHG
ZGI
ZXP
~KM
AALRI
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c534t-5f531527c9a2041f136b60083dd97fc98954857378a0902fbf1f8169e2cf490a3
ISSN 0090-9556
1521-009X
IngestDate Thu Aug 21 13:37:58 EDT 2025
Fri Sep 05 11:50:49 EDT 2025
Mon Jul 21 06:06:50 EDT 2025
Mon Jul 21 09:15:30 EDT 2025
Wed Sep 10 05:40:24 EDT 2025
Thu Apr 24 23:02:29 EDT 2025
Sun Apr 06 06:53:04 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords CV
DMET
P450
THLE
GAPDH
PCR
ACTB
PCA
Human
Cell line
Hepatocyte
Digestive system
Enzyme
Liver
Established cell line
Primary
Drug-metabolizing enzyme
In vitro
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c534t-5f531527c9a2041f136b60083dd97fc98954857378a0902fbf1f8169e2cf490a3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
OpenAccessLink https://dmd.aspetjournals.org/content/dmd/39/3/528.full.pdf
PMID 21149542
PQID 852910465
PQPubID 23479
PageCount 11
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_3061558
proquest_miscellaneous_852910465
pubmed_primary_21149542
pascalfrancis_primary_23928834
crossref_citationtrail_10_1124_dmd_110_035873
crossref_primary_10_1124_dmd_110_035873
elsevier_sciencedirect_doi_10_1124_dmd_110_035873
PublicationCentury 2000
PublicationDate 2011-03-01
PublicationDateYYYYMMDD 2011-03-01
PublicationDate_xml – month: 03
  year: 2011
  text: 2011-03-01
  day: 01
PublicationDecade 2010
PublicationPlace Bethesda, MD
PublicationPlace_xml – name: Bethesda, MD
– name: Netherlands
PublicationTitle Drug metabolism and disposition
PublicationTitleAlternate Drug Metab Dispos
PublicationYear 2011
Publisher Elsevier Inc
American Society for Pharmacology and Experimental Therapeutics
The American Society for Pharmacology and Experimental Therapeutics
Publisher_xml – name: Elsevier Inc
– name: American Society for Pharmacology and Experimental Therapeutics
– name: The American Society for Pharmacology and Experimental Therapeutics
References Ma, Woo, McLeod (bib23) 2002; 59
Fink, Ebbesen, Zachar (bib10) 2001; 11
Costa, Kalinichenko, Holterman, Wang (bib6) 2003; 38
Dykens, Jamieson, Marroquin, Nadanaciva, Xu, Dunn, Smith, Will (bib9) 2008; 103
Olsavsky, Page, Johnson, Zarbl, Strom, Omiecinski (bib25) 2007; 222
Wee, Yeo, Zhang, Tan, Lim, Tay, Go (bib35) 2009; 17
Aninat, Piton, Glaise, Le Charpentier, Langouët, Morel, Guguen-Guillouzo, Guillouzo (bib2) 2006; 34
Gilad, Rifkin, Pritchard (bib11) 2008; 24
Gómez-Lechón, Donato, Castell, Jover (bib12) 2003; 4
LeCluyse (bib22) 2001; 13
Jover, Bort, Gómez-Lechón, Castell (bib20) 1998; 431
Henzel, Thorborg, Hofmann, Zimmer, Leuschner (bib14) 2004; 1644
Walsky, Boldt (bib34) 2008; 9
Wilkening, Stahl, Bader (bib37) 2003; 31
Knasmüller, Mersch-Sundermann, Kevekordes, Darroudi, Huber, Hoelzl, Bichler, Majer (bib21) 2004; 198
Yang, Zhang, Molony, Chudin, Hao, Zhu, Gaedigk, Suver, Zhong, Leeder (bib38) 2010; 20
Rudzok, Schlink, Herbarth, Bauer (bib28) 2010; 244
Soars, McGinnity, Grime, Riley (bib31) 2007; 168
Doostdar, Duthie, Burke, Melvin, Grant (bib8) 1988; 241
Huang, Strong, Zhang, Reynolds, Nallani, Temple, Abraham, Habet, Baweja, Burckart (bib18) 2008; 48
Zhou, Liu, Chowbay (bib40) 2009; 41
Shiizaki, Ohsako, Koyama, Nagata, Yonemoto, Tohyama (bib30) 2005; 160
Hart, Li, Nakamoto, Subileau, Steen, Zhong (bib13) 2010; 38
Jennen, Magkoufopoulou, Ketelslegers, van Herwijnen, Kleinjans, van Delft (bib19) 2010; 115
Schadt, Molony, Chudin, Hao, Yang, Lum, Kasarskis, Zhang, Wang, Suver (bib29) 2008; 6
Cereghini (bib4) 1996; 10
Hewitt, Lechón, Houston, Hallifax, Brown, Maurel, Kenna, Gustavsson, Lohmann, Skonberg (bib15) 2007; 39
Brandon, Raap, Meijerman, Beijnen, Schellens (bib3) 2003; 189
Hewitt, Lecluyse, Ferguson (bib16) 2007; 37
Rodríguez-Antona, Donato, Pareja, Gómez-Lechón, Castell (bib27) 2001; 393
Ando, Saka, Ando, Sawa, Muro, Ueoka, Yokoyama, Saitoh, Shimokata, Hasegawa (bib1) 2000; 60
Hirth, Watkins, Strawderman, Schott, Bruno, Baker (bib17) 2000; 6
Westerink, Schoonen (bib36) 2007; 21
Donato, Lahoz, Castell, Gómez-Lechón (bib7) 2008; 9
Norppa (bib24) 1997; 105
Zhou, Di, Chan, Du, Chow, Xue, Lai, Wang, Li, Tian (bib39) 2008; 9
Chao, Tsou, Chen, Chang, Tsai, Lin, Chen, Wang (bib5) 2009; 170
Strom, Pisarov, Dorko, Thompson, Schuetz, Schuetz (bib32) 1996; 272
Pfeifer, Cole, Smoot, Weston, Groopman, Shields, Vignaud, Juillerat, Lipsky, Trump (bib26) 1993; 90
Suzuki, Oguro, Osada-Oka, Funae, Imaoka (bib33) 2008; 108
Zhou (10.1124/dmd.110.035873_bib39) 2008; 9
Soars (10.1124/dmd.110.035873_bib31) 2007; 168
Westerink (10.1124/dmd.110.035873_bib36) 2007; 21
Hart (10.1124/dmd.110.035873_bib13) 2010; 38
Aninat (10.1124/dmd.110.035873_bib2) 2006; 34
Knasmüller (10.1124/dmd.110.035873_bib21) 2004; 198
Henzel (10.1124/dmd.110.035873_bib14) 2004; 1644
Ma (10.1124/dmd.110.035873_bib23) 2002; 59
Jover (10.1124/dmd.110.035873_bib20) 1998; 431
Doostdar (10.1124/dmd.110.035873_bib8) 1988; 241
Dykens (10.1124/dmd.110.035873_bib9) 2008; 103
Olsavsky (10.1124/dmd.110.035873_bib25) 2007; 222
Fink (10.1124/dmd.110.035873_bib10) 2001; 11
Pfeifer (10.1124/dmd.110.035873_bib26) 1993; 90
Ando (10.1124/dmd.110.035873_bib1) 2000; 60
Brandon (10.1124/dmd.110.035873_bib3) 2003; 189
Hewitt (10.1124/dmd.110.035873_bib15) 2007; 39
Huang (10.1124/dmd.110.035873_bib18) 2008; 48
Yang (10.1124/dmd.110.035873_bib38) 2010; 20
Zhou (10.1124/dmd.110.035873_bib40) 2009; 41
Walsky (10.1124/dmd.110.035873_bib34) 2008; 9
Rodríguez-Antona (10.1124/dmd.110.035873_bib27) 2001; 393
Schadt (10.1124/dmd.110.035873_bib29) 2008; 6
Norppa (10.1124/dmd.110.035873_bib24) 1997; 105
Cereghini (10.1124/dmd.110.035873_bib4) 1996; 10
Costa (10.1124/dmd.110.035873_bib6) 2003; 38
Jennen (10.1124/dmd.110.035873_bib19) 2010; 115
Wilkening (10.1124/dmd.110.035873_bib37) 2003; 31
Suzuki (10.1124/dmd.110.035873_bib33) 2008; 108
Gilad (10.1124/dmd.110.035873_bib11) 2008; 24
LeCluyse (10.1124/dmd.110.035873_bib22) 2001; 13
Strom (10.1124/dmd.110.035873_bib32) 1996; 272
Wee (10.1124/dmd.110.035873_bib35) 2009; 17
Rudzok (10.1124/dmd.110.035873_bib28) 2010; 244
Hewitt (10.1124/dmd.110.035873_bib16) 2007; 37
Donato (10.1124/dmd.110.035873_bib7) 2008; 9
Shiizaki (10.1124/dmd.110.035873_bib30) 2005; 160
Chao (10.1124/dmd.110.035873_bib5) 2009; 170
Hirth (10.1124/dmd.110.035873_bib17) 2000; 6
Gómez-Lechón (10.1124/dmd.110.035873_bib12) 2003; 4
References_xml – volume: 9
  start-page: 1
  year: 2008
  end-page: 11
  ident: bib7
  article-title: Cell lines: a tool for in vitro drug metabolism studies
  publication-title: Curr Drug Metab
– volume: 6
  start-page: 1255
  year: 2000
  end-page: 1258
  ident: bib17
  article-title: The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance
  publication-title: Clin Cancer Res
– volume: 48
  start-page: 662
  year: 2008
  end-page: 670
  ident: bib18
  article-title: New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process
  publication-title: J Clin Pharmacol
– volume: 31
  start-page: 1035
  year: 2003
  end-page: 1042
  ident: bib37
  article-title: Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties
  publication-title: Drug Metab Dispos
– volume: 393
  start-page: 308
  year: 2001
  end-page: 315
  ident: bib27
  article-title: Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity
  publication-title: Arch Biochem Biophys
– volume: 9
  start-page: 928
  year: 2008
  end-page: 939
  ident: bib34
  article-title: In vitro cytochrome P450 inhibition and induction
  publication-title: Curr Drug Metab
– volume: 38
  start-page: 988
  year: 2010
  end-page: 994
  ident: bib13
  article-title: A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues
  publication-title: Drug Metab Dispos
– volume: 244
  start-page: 336
  year: 2010
  end-page: 343
  ident: bib28
  article-title: Measuring and modeling of binary mixture effects of pharmaceuticals and nickel on cell viability/cytotoxicity in the human hepatoma derived cell line HepG2
  publication-title: Toxicol Appl Pharmacol
– volume: 34
  start-page: 75
  year: 2006
  end-page: 83
  ident: bib2
  article-title: Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells
  publication-title: Drug Metab Dispos
– volume: 21
  start-page: 1581
  year: 2007
  end-page: 1591
  ident: bib36
  article-title: Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells
  publication-title: Toxicol In Vitro
– volume: 189
  start-page: 233
  year: 2003
  end-page: 246
  ident: bib3
  article-title: An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons
  publication-title: Toxicol Appl Pharmacol
– volume: 17
  start-page: 7562
  year: 2009
  end-page: 7571
  ident: bib35
  article-title: Synthesis and evaluation of functionalized isoindigos as antiproliferative agents
  publication-title: Bioorg Med Chem
– volume: 10
  start-page: 267
  year: 1996
  end-page: 282
  ident: bib4
  article-title: Liver-enriched transcription factors and hepatocyte differentiation
  publication-title: FASEB J
– volume: 222
  start-page: 42
  year: 2007
  end-page: 56
  ident: bib25
  article-title: Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues
  publication-title: Toxicol Appl Pharmacol
– volume: 41
  start-page: 89
  year: 2009
  end-page: 295
  ident: bib40
  article-title: Polymorphism of human cytochrome P450 enzymes and its clinical impact
  publication-title: Drug Metab Rev
– volume: 115
  start-page: 66
  year: 2010
  end-page: 79
  ident: bib19
  article-title: Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification
  publication-title: Toxicol Sci
– volume: 103
  start-page: 335
  year: 2008
  end-page: 345
  ident: bib9
  article-title: In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone
  publication-title: Toxicol Sci
– volume: 38
  start-page: 1331
  year: 2003
  end-page: 1347
  ident: bib6
  article-title: Transcription factors in liver development, differentiation, and regeneration
  publication-title: Hepatology
– volume: 59
  start-page: 2061
  year: 2002
  end-page: 2069
  ident: bib23
  article-title: Genetic basis of drug metabolism
  publication-title: Am J Health Syst Pharm
– volume: 20
  start-page: 1020
  year: 2010
  end-page: 1036
  ident: bib38
  article-title: Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver
  publication-title: Genome Res
– volume: 11
  start-page: 105
  year: 2001
  end-page: 114
  ident: bib10
  article-title: Quantitative gene expression profiles of human liver-derived cell lines exposed to moderate hypoxia
  publication-title: Cell Physiol Biochem
– volume: 13
  start-page: 343
  year: 2001
  end-page: 368
  ident: bib22
  article-title: Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation
  publication-title: Eur J Pharm Sci
– volume: 272
  start-page: 388
  year: 1996
  end-page: 401
  ident: bib32
  article-title: Use of human hepatocytes to study P450 gene induction
  publication-title: Methods Enzymol
– volume: 60
  start-page: 6921
  year: 2000
  end-page: 6926
  ident: bib1
  article-title: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis
  publication-title: Cancer Res
– volume: 170
  start-page: 351
  year: 2009
  end-page: 356
  ident: bib5
  article-title: The inhibition effect of 2,3,7,8-tetrachlorinated dibenzo-p-dioxin-induced aryl hydrocarbon receptor activation in human hepatoma cells with the treatment of cadmium chloride
  publication-title: J Hazard Mater
– volume: 37
  start-page: 1196
  year: 2007
  end-page: 1224
  ident: bib16
  article-title: Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations
  publication-title: Xenobiotica
– volume: 6
  start-page: e107
  year: 2008
  ident: bib29
  article-title: Mapping the genetic architecture of gene expression in human liver
  publication-title: PLoS Biol
– volume: 9
  start-page: 738
  year: 2008
  end-page: 784
  ident: bib39
  article-title: Clinical pharmacogenetics and potential application in personalized medicine
  publication-title: Curr Drug Metab
– volume: 160
  start-page: 22
  year: 2005
  end-page: 33
  ident: bib30
  article-title: Lack of CYP1A1 expression is involved in unresponsiveness of the human hepatoma cell line SK-HEP-1 to dioxin
  publication-title: Toxicol Lett
– volume: 24
  start-page: 408
  year: 2008
  end-page: 415
  ident: bib11
  article-title: Revealing the architecture of gene regulation: the promise of eQTL studies
  publication-title: Trends Genet
– volume: 198
  start-page: 315
  year: 2004
  end-page: 328
  ident: bib21
  article-title: Use of human-derived liver cell lines for the detection of environmental and dietary genotoxicants; current state of knowledge
  publication-title: Toxicology
– volume: 4
  start-page: 292
  year: 2003
  end-page: 312
  ident: bib12
  article-title: Human hepatocytes as a tool for studying toxicity and drug metabolism
  publication-title: Curr Drug Metab
– volume: 431
  start-page: 227
  year: 1998
  end-page: 230
  ident: bib20
  article-title: Re-expression of C/EBPα induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells
  publication-title: FEBS Lett
– volume: 108
  start-page: 79
  year: 2008
  end-page: 88
  ident: bib33
  article-title: Epoxyeicosatrienoic acids and/or their metabolites promote hypoxic response of cells
  publication-title: J Pharmacol Sci
– volume: 1644
  start-page: 37
  year: 2004
  end-page: 45
  ident: bib14
  article-title: Toxicity of ethanol and acetaldehyde in hepatocytes treated with ursodeoxycholic or tauroursodeoxycholic acid
  publication-title: Biochim Biophys Acta
– volume: 241
  start-page: 15
  year: 1988
  end-page: 18
  ident: bib8
  article-title: The influence of culture medium composition on drug metabolising enzyme activities of the human liver derived Hep G2 cell line
  publication-title: FEBS Lett
– volume: 90
  start-page: 5123
  year: 1993
  end-page: 5127
  ident: bib26
  article-title: Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens
  publication-title: Proc Natl Acad Sci USA
– volume: 105
  start-page: 829
  year: 1997
  end-page: 835
  ident: bib24
  article-title: Cytogenetic markers of susceptibility: influence of polymorphic carcinogen-metabolizing enzymes
  publication-title: Environ Health Perspect
– volume: 39
  start-page: 159
  year: 2007
  end-page: 234
  ident: bib15
  article-title: Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies
  publication-title: Drug Metab Rev
– volume: 168
  start-page: 2
  year: 2007
  end-page: 15
  ident: bib31
  article-title: The pivotal role of hepatocytes in drug discovery
  publication-title: Chem Biol Interact
– volume: 38
  start-page: 1331
  year: 2003
  ident: 10.1124/dmd.110.035873_bib6
  article-title: Transcription factors in liver development, differentiation, and regeneration
  publication-title: Hepatology
  doi: 10.1016/j.hep.2003.09.034
– volume: 24
  start-page: 408
  year: 2008
  ident: 10.1124/dmd.110.035873_bib11
  article-title: Revealing the architecture of gene regulation: the promise of eQTL studies
  publication-title: Trends Genet
  doi: 10.1016/j.tig.2008.06.001
– volume: 13
  start-page: 343
  year: 2001
  ident: 10.1124/dmd.110.035873_bib22
  article-title: Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation
  publication-title: Eur J Pharm Sci
  doi: 10.1016/S0928-0987(01)00135-X
– volume: 48
  start-page: 662
  year: 2008
  ident: 10.1124/dmd.110.035873_bib18
  article-title: New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process
  publication-title: J Clin Pharmacol
  doi: 10.1177/0091270007312153
– volume: 222
  start-page: 42
  year: 2007
  ident: 10.1124/dmd.110.035873_bib25
  article-title: Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues
  publication-title: Toxicol Appl Pharmacol
  doi: 10.1016/j.taap.2007.03.032
– volume: 9
  start-page: 1
  year: 2008
  ident: 10.1124/dmd.110.035873_bib7
  article-title: Cell lines: a tool for in vitro drug metabolism studies
  publication-title: Curr Drug Metab
  doi: 10.2174/138920008783331086
– volume: 431
  start-page: 227
  year: 1998
  ident: 10.1124/dmd.110.035873_bib20
  article-title: Re-expression of C/EBPα induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells
  publication-title: FEBS Lett
  doi: 10.1016/S0014-5793(98)00746-7
– volume: 160
  start-page: 22
  year: 2005
  ident: 10.1124/dmd.110.035873_bib30
  article-title: Lack of CYP1A1 expression is involved in unresponsiveness of the human hepatoma cell line SK-HEP-1 to dioxin
  publication-title: Toxicol Lett
  doi: 10.1016/j.toxlet.2005.06.003
– volume: 17
  start-page: 7562
  year: 2009
  ident: 10.1124/dmd.110.035873_bib35
  article-title: Synthesis and evaluation of functionalized isoindigos as antiproliferative agents
  publication-title: Bioorg Med Chem
  doi: 10.1016/j.bmc.2009.09.008
– volume: 31
  start-page: 1035
  year: 2003
  ident: 10.1124/dmd.110.035873_bib37
  article-title: Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.31.8.1035
– volume: 115
  start-page: 66
  year: 2010
  ident: 10.1124/dmd.110.035873_bib19
  article-title: Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification
  publication-title: Toxicol Sci
  doi: 10.1093/toxsci/kfq026
– volume: 59
  start-page: 2061
  year: 2002
  ident: 10.1124/dmd.110.035873_bib23
  article-title: Genetic basis of drug metabolism
  publication-title: Am J Health Syst Pharm
  doi: 10.1093/ajhp/59.21.2061
– volume: 244
  start-page: 336
  year: 2010
  ident: 10.1124/dmd.110.035873_bib28
  article-title: Measuring and modeling of binary mixture effects of pharmaceuticals and nickel on cell viability/cytotoxicity in the human hepatoma derived cell line HepG2
  publication-title: Toxicol Appl Pharmacol
  doi: 10.1016/j.taap.2010.01.012
– volume: 90
  start-page: 5123
  year: 1993
  ident: 10.1124/dmd.110.035873_bib26
  article-title: Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.90.11.5123
– volume: 108
  start-page: 79
  year: 2008
  ident: 10.1124/dmd.110.035873_bib33
  article-title: Epoxyeicosatrienoic acids and/or their metabolites promote hypoxic response of cells
  publication-title: J Pharmacol Sci
  doi: 10.1254/jphs.08122FP
– volume: 38
  start-page: 988
  year: 2010
  ident: 10.1124/dmd.110.035873_bib13
  article-title: A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.109.031831
– volume: 9
  start-page: 928
  year: 2008
  ident: 10.1124/dmd.110.035873_bib34
  article-title: In vitro cytochrome P450 inhibition and induction
  publication-title: Curr Drug Metab
  doi: 10.2174/138920008786485128
– volume: 393
  start-page: 308
  year: 2001
  ident: 10.1124/dmd.110.035873_bib27
  article-title: Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity
  publication-title: Arch Biochem Biophys
  doi: 10.1006/abbi.2001.2499
– volume: 21
  start-page: 1581
  year: 2007
  ident: 10.1124/dmd.110.035873_bib36
  article-title: Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells
  publication-title: Toxicol In Vitro
  doi: 10.1016/j.tiv.2007.05.014
– volume: 34
  start-page: 75
  year: 2006
  ident: 10.1124/dmd.110.035873_bib2
  article-title: Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.105.006759
– volume: 272
  start-page: 388
  year: 1996
  ident: 10.1124/dmd.110.035873_bib32
  article-title: Use of human hepatocytes to study P450 gene induction
  publication-title: Methods Enzymol
  doi: 10.1016/S0076-6879(96)72044-X
– volume: 105
  start-page: 829
  issue: Suppl 4
  year: 1997
  ident: 10.1124/dmd.110.035873_bib24
  article-title: Cytogenetic markers of susceptibility: influence of polymorphic carcinogen-metabolizing enzymes
  publication-title: Environ Health Perspect
  doi: 10.1289/ehp.97105s4829
– volume: 39
  start-page: 159
  year: 2007
  ident: 10.1124/dmd.110.035873_bib15
  article-title: Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies
  publication-title: Drug Metab Rev
  doi: 10.1080/03602530601093489
– volume: 241
  start-page: 15
  year: 1988
  ident: 10.1124/dmd.110.035873_bib8
  article-title: The influence of culture medium composition on drug metabolising enzyme activities of the human liver derived Hep G2 cell line
  publication-title: FEBS Lett
  doi: 10.1016/0014-5793(88)81021-4
– volume: 11
  start-page: 105
  year: 2001
  ident: 10.1124/dmd.110.035873_bib10
  article-title: Quantitative gene expression profiles of human liver-derived cell lines exposed to moderate hypoxia
  publication-title: Cell Physiol Biochem
  doi: 10.1159/000047798
– volume: 6
  start-page: 1255
  year: 2000
  ident: 10.1124/dmd.110.035873_bib17
  article-title: The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance
  publication-title: Clin Cancer Res
– volume: 189
  start-page: 233
  year: 2003
  ident: 10.1124/dmd.110.035873_bib3
  article-title: An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons
  publication-title: Toxicol Appl Pharmacol
  doi: 10.1016/S0041-008X(03)00128-5
– volume: 6
  start-page: e107
  year: 2008
  ident: 10.1124/dmd.110.035873_bib29
  article-title: Mapping the genetic architecture of gene expression in human liver
  publication-title: PLoS Biol
  doi: 10.1371/journal.pbio.0060107
– volume: 20
  start-page: 1020
  year: 2010
  ident: 10.1124/dmd.110.035873_bib38
  article-title: Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver
  publication-title: Genome Res
  doi: 10.1101/gr.103341.109
– volume: 60
  start-page: 6921
  year: 2000
  ident: 10.1124/dmd.110.035873_bib1
  article-title: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis
  publication-title: Cancer Res
– volume: 10
  start-page: 267
  year: 1996
  ident: 10.1124/dmd.110.035873_bib4
  article-title: Liver-enriched transcription factors and hepatocyte differentiation
  publication-title: FASEB J
  doi: 10.1096/fasebj.10.2.8641560
– volume: 103
  start-page: 335
  year: 2008
  ident: 10.1124/dmd.110.035873_bib9
  article-title: In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone
  publication-title: Toxicol Sci
  doi: 10.1093/toxsci/kfn056
– volume: 41
  start-page: 89
  year: 2009
  ident: 10.1124/dmd.110.035873_bib40
  article-title: Polymorphism of human cytochrome P450 enzymes and its clinical impact
  publication-title: Drug Metab Rev
  doi: 10.1080/03602530902843483
– volume: 168
  start-page: 2
  year: 2007
  ident: 10.1124/dmd.110.035873_bib31
  article-title: The pivotal role of hepatocytes in drug discovery
  publication-title: Chem Biol Interact
  doi: 10.1016/j.cbi.2006.11.002
– volume: 9
  start-page: 738
  year: 2008
  ident: 10.1124/dmd.110.035873_bib39
  article-title: Clinical pharmacogenetics and potential application in personalized medicine
  publication-title: Curr Drug Metab
  doi: 10.2174/138920008786049302
– volume: 37
  start-page: 1196
  year: 2007
  ident: 10.1124/dmd.110.035873_bib16
  article-title: Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations
  publication-title: Xenobiotica
  doi: 10.1080/00498250701534893
– volume: 170
  start-page: 351
  year: 2009
  ident: 10.1124/dmd.110.035873_bib5
  article-title: The inhibition effect of 2,3,7,8-tetrachlorinated dibenzo-p-dioxin-induced aryl hydrocarbon receptor activation in human hepatoma cells with the treatment of cadmium chloride
  publication-title: J Hazard Mater
  doi: 10.1016/j.jhazmat.2009.04.090
– volume: 198
  start-page: 315
  year: 2004
  ident: 10.1124/dmd.110.035873_bib21
  article-title: Use of human-derived liver cell lines for the detection of environmental and dietary genotoxicants; current state of knowledge
  publication-title: Toxicology
  doi: 10.1016/j.tox.2004.02.008
– volume: 4
  start-page: 292
  year: 2003
  ident: 10.1124/dmd.110.035873_bib12
  article-title: Human hepatocytes as a tool for studying toxicity and drug metabolism
  publication-title: Curr Drug Metab
  doi: 10.2174/1389200033489424
– volume: 1644
  start-page: 37
  year: 2004
  ident: 10.1124/dmd.110.035873_bib14
  article-title: Toxicity of ethanol and acetaldehyde in hepatocytes treated with ursodeoxycholic or tauroursodeoxycholic acid
  publication-title: Biochim Biophys Acta
  doi: 10.1016/j.bbamcr.2003.10.017
SSID ssj0014439
Score 2.4966726
Snippet In addition to primary human hepatocytes, hepatoma cell lines, and transfected nonhepatoma, hepatic cell lines have been used for pharmacological and...
SourceID pubmedcentral
proquest
pubmed
pascalfrancis
crossref
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 528
SubjectTerms Algorithms
Biological and medical sciences
Biological Transport
Cell Line
Cell Line, Tumor
Cells, Cultured
Drug Evaluation, Preclinical - methods
Gene Expression Profiling
Gene Expression Regulation, Enzymologic
Hepatocytes - enzymology
Hepatocytes - metabolism
Humans
Inactivation, Metabolic
Medical sciences
Membrane Transport Proteins - genetics
Membrane Transport Proteins - metabolism
Oligonucleotide Array Sequence Analysis
Pharmacokinetics
Pharmacology. Drug treatments
Reverse Transcriptase Polymerase Chain Reaction
RNA, Messenger - metabolism
Title Similarities and Differences in the Expression of Drug-Metabolizing Enzymes between Human Hepatic Cell Lines and Primary Human Hepatocytes
URI https://dx.doi.org/10.1124/dmd.110.035873
https://www.ncbi.nlm.nih.gov/pubmed/21149542
https://www.proquest.com/docview/852910465
https://pubmed.ncbi.nlm.nih.gov/PMC3061558
Volume 39
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1521-009X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0014439
  issn: 0090-9556
  databaseCode: KQ8
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswECXc9FKgKLrHXQIeivTQKJUoUsvRTd06bZwusYHcBC1kKyCRjUQGan9C_6__0-Eiic6CLhdBsChR1jyRM6PHNwi9CDye-izIHJ_xwKGEBk5UhMLJPMLjKOdFLmRqYHwYjKb0wzE77vV-WaylRZ3t5qsr15X8j1XhN7CrXCX7D5ZtLwo_wD7YF7ZgYdj-lY2PytMSIlMliqo5xabciaZZKady-MNQXZVf-PZs8c0Z8xpMf1KuZJpgWK2WUrCpIWzprP6Iz5WU655M7R1IarxZVqC1KaxGs3xZGx6i8XFlH7IyterDlOAoypYe1lKAhvuv3k8_tZ70_uBA087SnC-7RmOZTjsatcndN18Hh6PBWHEDda7ITlx4FnPLWisgBzGLnvq50-vW8lNDu87BpFuSZmcy3dh1Yqb1yZtBXSskGfD61gjNzFp0PdkzLS1zeR4hFIxfnBZymcSu67NIF1xZF-y-MJG29EYCTmcU-fQGuknCIJCFNT5-6T5uUerrqMzct9EShT5fr_d4na90e56ewxssdOmVq2KjixRfy2ea3EV3TLCDBxq591CPV_fRtnn6yx1sP-kdvI1tuzxAP214YzATtuCNywoDvHEHbzwT-BK8sYE3NvDGCrnYwBtLeGMFb3V9A2-7kYb3QzR9N5zsjRxTOsTJmU9rhwmYWxgJ8zglLvWE5wdZIMONoohDkceR1DlkoR9GqSQmi0x4IvKCmJNc0NhN_Udoo5pVfBPhyKVBnsYey4S8EsvAZfc4TVMBR9yM95HTGCnJja6-LO9ykqj4mtAEjAo7bqKN2kcv2_Zz_beubek1Nk-MP6z93ARgeu05W2vgaLtoMNlHuEFLAjOJ_DyYVny2OE8iRmLJ-GB99FiDpzvZk4kUSvooXINV20CK1K8fqcrvSqzelzETi5786b6eolvdIPEMbdRnC_4c_P0621Jvz28SMgk1
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Similarities+and+Differences+in+the+Expression+of+Drug-Metabolizing+Enzymes+between+Human+Hepatic+Cell+Lines+and+Primary+Human+Hepatocytes&rft.jtitle=Drug+metabolism+and+disposition&rft.au=LEI+GUO&rft.au=DIAL%2C+Stacey&rft.au=LEMING+SHI&rft.au=BRANHAM%2C+William&rft.date=2011-03-01&rft.pub=American+Society+for+Pharmacology+and+Experimental+Therapeutics&rft.issn=0090-9556&rft.volume=39&rft.issue=3&rft.spage=528&rft.epage=538&rft_id=info:doi/10.1124%2Fdmd.110.035873&rft.externalDBID=n%2Fa&rft.externalDocID=23928834
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-9556&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-9556&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-9556&client=summon